Your Search Results

How to face resistent hypertension: when pharmacological treatment is not an option

19 May 2026 – From EuroPCR 2026

Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

19 May 2026 – From EuroPCR 2026

A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.

Lesion preparation was performed with...

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

TAVI procedural complications - Part 3: vascular complications, coronary issues and more

19 May 2026 – From EuroPCR 2026

This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.

Identifying problems and solving complex anatomies during TAVI

19 May 2026 – From EuroPCR 2026

A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.

2026 Andreas Grüntzig Ethica Awardee: Roxana Mehran

20 May 2026

The Andreas Grüntzig Ethica Award – the highest honour in the interventional cardiology community – is presented to individuals who have contributed in an extraordinary way to the PCR mission.

INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

03 Sep 2024

Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.